Histogen Management

Management Kriterienprüfungen 2/4

Wir verfügen derzeit nicht über ausreichende Informationen über den CEO.

Wichtige Informationen

Susan Knudson

Geschäftsführender

US$681.2k

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	68.4%
Amtszeit als Geschäftsführer	4.1yrs
Eigentum des Geschäftsführers	n/a
Durchschnittliche Amtszeit des Managements	keine Daten
Durchschnittliche Amtszeit der Vorstandsmitglieder	10.3yrs

Jüngste Management Updates

Recent updates

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Susan Knudson im Vergleich zu den Einnahmen von Histogen verändert?
Datum	Gesamtvergütung	Gehalt	Unternehmensgewinne
Sep 30 2023	n/a	n/a	-US$12m
Jun 30 2023	n/a	n/a	-US$12m
Mar 31 2023	n/a	n/a	-US$14m
Dec 31 2022	US$681k	US$466k	-US$11m
Sep 30 2022	n/a	n/a	-US$11m
Jun 30 2022	n/a	n/a	-US$12m
Mar 31 2022	n/a	n/a	-US$11m
Dec 31 2021	US$539k	US$385k	-US$15m
Sep 30 2021	n/a	n/a	-US$15m
Jun 30 2021	n/a	n/a	-US$15m
Mar 31 2021	n/a	n/a	-US$21m
Dec 31 2020	US$767k	US$212k	-US$19m

Vergütung im Vergleich zum Markt: SusanDie Gesamtvergütung ($USD681.24K) liegt im Durchschnitt der Unternehmen ähnlicher Größe auf dem Markt US ($USD667.11K).

Entschädigung vs. Einkommen: SusanDie Bezüge der Mitarbeiter sind gestiegen, während das Unternehmen unrentabel ist.

Geschäftsführer

Susan Knudson (60 yo)

4.1yrs

Amtszeit

US$681,237

Vergütung

Ms. Susan A. Knudson is Chief Financial Officer of Histogen Inc. since May 2020 and serves as its Chief Compliance Officer and Corporate Secretary and serves as its Chief Operations Officer since March 10,...

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Daniel Kisner	Independent Non-Executive Chairman	10.3yrs	US$52.70k	0.0011% $ 14.1
Neil Sadick	Member of the Scientific Advisory Board	13.9yrs	keine Daten	keine Daten
Craig Ziering	Member of Scientific Advisory Board	no data	keine Daten	keine Daten
Susan Windham-Bannister	Independent Director	3.3yrs	US$57.70k	0% $ 0
Rochelle Fuhrmann	Independent Director	3.3yrs	US$58.81k	0% $ 0
Dale DeVore	Member of the Scientific Advisory Board	no data	keine Daten	keine Daten
David Crean	Independent Director	6.3yrs	US$85.24k	0% $ 0
Jonathan Jackson	Independent Director	13.5yrs	US$51.05k	2.76% $ 35.3k
David Easter	Member of Scientific Advisory Board	no data	keine Daten	keine Daten
Brian Satz	Independent Director	11.6yrs	US$56.70k	0.0017% $ 21.7

10.3yrs

Durchschnittliche Betriebszugehörigkeit

62yo

Durchschnittliches Alter

Erfahrener Vorstand: HSTODie Vorstandsmitglieder sind sehr erfahren ( 10.3 ).

Histogen Management

Management Kriterienprüfungen 2/4

Wichtige Informationen

Jüngste Management Updates

Histogen Inc. Announces Executive Changes

Histogen Inc. Hires Alfred P. Spada as Chief Scientific Officer

Histogen Inc., Annual General Meeting, Jun 01, 2022

Histogen Inc. Announces Board Changes

Histogen Inc. Appoints Moya Daniels as Executive Vice President and Head of Regulatory, Quality and Clinical Operations

Recent updates

Histogen Inc. Filed for Bankruptcy

Histogen Inc. Files Form 15

Histogen Inc.(OTCPK:HSTO) dropped from NASDAQ Composite Index

Nasdaq To File A Form 25-NSE with the SEC, To Remove Histogen's Securities from Listing and Registration

Histogen Inc.(NasdaqCM:HSTO) dropped from S&P TMI Index

Histogen Inc. Announces Executive Changes

Histogen Intends to File Certificate of Dissolution, Delist its Shares of Common Stock from The Nasdaq Capital Market

Histogen Receives Letter from the Listing Qualifications Department of the Nasdaq Regarding Listing Rule 5550(a)(2)

Histogen Inc. Hires Alfred P. Spada as Chief Scientific Officer

Histogen stock down 8% after Q2 loss, on track for six-day losing streak

Histogen Inc. to Report Q2, 2022 Results on Aug 11, 2022

Histogen Inc. announced that it expects to receive $5 million in funding

Histogen announces pricing of $5M private placement

Histogen Announces 1-for-20 Reverse Stock Split

First quarter 2022 earnings released: US$0.013 loss per share (vs US$0.14 loss in 1Q 2021)

Price target decreased to US$2.25

Histogen Inc., Annual General Meeting, Jun 01, 2022

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Histogen Inc. to Report Q4, 2021 Results on Mar 10, 2022

Histogen Not Regained Compliance with the Minimum Bid Price Requirement

Histogen Inc. announced that it has received $3.500001 million in funding

Histogen Inc. announced that it expects to receive $3.500001 million in funding

We're A Little Worried About Histogen's (NASDAQ:HSTO) Cash Burn Rate

Histogen Announces Initiation of HST 003 Phase 1/2 Trial for Knee Cartilage Regeneration

Histogen Inc. and its partner Amerimmune LLC Announce Positive Top-Line Study Results from its Phase 1 Study of Emricasan in Mild Symptomatic COVID-19 Patients

Histogen jumps 11% after Intracoastal Capital reports 5.6% stake

Histogen Inc. has completed a Follow-on Equity Offering in the amount of $6.57503 million.

Histogen enters $6.5M at-the-market direct offering

Histogen Provides Update on its Development Programs and Pipeline Focus

Histogen and Amerimmune Reports Publication on Emricasan in COVID-19

First quarter 2021 earnings released: US$0.14 loss per share (vs US$0.55 loss in 1Q 2020)

Histogen Provides Business Update

Histogen and Amerimmune Announce First Patient Dosed in Phase 1 Study of Emricasan in Symptomatic Covid-19 Patients

Histogen Announces Removal of Clinical Hold by FDA for HST-003 IND to Initiate a Phase 1/2 Trial for Knee Cartilage Regeneration

Full year 2020 earnings released: US$2.08 loss per share (vs US$0.89 loss in FY 2019)

Histogen Inc. Announces Board Changes

Independent Director has left the company

Histogen Inc. to Report Q4, 2020 Results on Mar 11, 2021

Histogen Announces Week 26 HST-001 Study Results for the Treatment of Androgenic Alopecia in Men

New 90-day high: US$1.72

Histogen Inc. Reports FDA Clinical Hold for Planned Phase 1/2 Trial of HST-003 for Knee Cartilage Regeneration

Histogen Inc. has completed a Follow-on Equity Offering in the amount of $14 million.

Histogen under pressure on pricing $14M upsized public offering

Histogen Inc. Announces Filing an Investigational New Drug Application for HST-003

New 90-day low: US$1.19

Histogen files IND application for regenerative human matrix

Histogen Announces Preliminary Week 18 HST-001 Study Results for the Treatment of Androgenic Alopecia in Men

New 90-day low: US$1.31

Histogen soars after HST-001 data in male pattern baldness

Histogen Inc. has completed a Follow-on Equity Offering in the amount of $4.500016 million.

Histogen Inc. to Report Q3, 2020 Results on Nov 12, 2020

Histogen Inc. and Amerimmune Llc Enters into A Collaborative Development and Commercialization Agreement for Emricasan in the Treatment of Covid-19

Histogen Inc. Appoints Moya Daniels as Executive Vice President and Head of Regulatory, Quality and Clinical Operations

Histogen Announces Completion of Final Dosing Timepoint Milestone in its 1b/2a Trial for Androgenic Alopecia in Men

Histogen Announces Update for its HST-002 Dermal Filler Program

Histogen Inc. Announces Phase 1/2 Clinical Trial Designed to Evaluate HST-003

New 90-day low - US$1.64

First half earnings released

Histogen Inc. to Report Q2, 2020 Results on Aug 13, 2020